Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised options and sold 6,500 shares of common stock for a profit.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), engaged in a stock transaction on November 18, 2025.
• Moreadith exercised 6,500 stock options at an exercise price of $0.06 per share.
• Concurrently, Moreadith sold 6,500 shares of common stock at a weighted average price of $3.7541 per share.
• The sale price for the common stock ranged from $3.71 to $3.90 per share.
• Following these transactions, Moreadith directly owns 0 shares of common stock but retains 384,686 stock options.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The transaction reflects an insider taking profits on vested options, which is a normal part of executive compensation. The sale was pre-planned under a 10b5-1 plan, mitigating concerns about opportunistic selling. However, the reduction of direct common stock holdings to zero could be viewed with slight caution, though a substantial number of options remain.

Positives

• The Chief Scientific Officer realized a significant profit by exercising options at $0.06 and selling shares at an average of $3.7541.
• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate insider information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, especially when it reduces direct common stock holdings to zero.

Future Outlook

NA

Industry Context

This is an insider transaction report, which is a routine disclosure for publicly traded companies. It reflects individual executive compensation and liquidity management rather than broader industry trends or company-specific operational performance.

Stakeholder Impact

• Shareholders may note the Chief Scientific Officer's decision to monetize a portion of his equity compensation, which is a common practice. The transaction was pre-planned, which generally reduces concerns about its implications.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction where the Chief Scientific Officer exercised vested options and sold the acquired shares for a profit. While the direct common stock holding is now zero, the officer retains a substantial number of stock options. This transaction does not provide new fundamental information about the company's operational performance or future prospects to warrant a change in investment thesis. Investors should 'hold' and monitor future company performance and other disclosures.

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan